Monitor for initial first-in-human results of ATR-COSF by year-end 2026, which could provide the first clinical validation for the cosmetic program. Also track enrollment updates for the expanded ATR-04 Phase 1/2 trial, as patient recruitment into the new KRAS/MEK inhibitor cohorts will be a key catalyst.
Drugs in focus
AZTR drug pipeline →ATR-04
◆ Mixed Named in this 8-K- Impact
- Phase
- Phase 1/2
- Time to market
- Unknown — at least 3-5 years if Phase 1/2 data is positive, followed by Phase 3 trials and FDA review. The Fast Track designation could accelerate the timeline.
- Next catalyst
- None dated
What to watchWatch for ATR-04 Phase 1/2 first-cohort topline data expected Q4 2026, positive safety/efficacy signals could drive a sharp rally given the tiny market cap, but the ~6-month cash runway means a dilutive financing is likely before year-end regardless of results. The stock is a high-risk binary play on a single early-stage asset.
How the stock moved after the report
⚠ Clustered NEUTRAL VIEWSTOCK BELOW ENTRY AT T+1- T+0 · Nov 10 $0.6000entry
- T+1 · 6d ago −2.47%α −3.79% · $0.5852
- T+5 · due 9h ago Pending
- T+5 · todayOpen
- T+20 · in 22d Pending
- T+60 · in 3mo Pending
Price Chart
How similar events traded
Executive Summary
Azitra issued a press release announcing a presentation at BIO-Europe showing ex vivo data for ATR-COSF (a recombinant filaggrin protein cosmetic) with a 56% reduction in wrinkles from baseline, and an update on the ATR-04 Phase 1/2 trial expansion to include KRAS and MEK inhibitor patients. No financial data, guidance, or material corporate events were disclosed; the filing is a routine pipeline update.
Key Facts
- Azitra will present at BIO-Europe on November 10, 2026, showing ATR-COSF ex vivo data: a 56% reduction in wrinkles from baseline in a human torso skin model.
- ATR-COSF improved elasticity and wrinkle depth vs vehicle in ex vivo models at 48 hours.
- Initial results from the first-in-human study of ATR-COSF are anticipated by year-end 2026.
- The Phase 1/2 trial of ATR-04 was expanded in October 2026 to include patients with rashes due to KRAS and MEK inhibitors, and NF1 patients with MEK inhibitor-associated rash.
- Approximately 85,000 patients undergo KRAS or MEK inhibitor treatment annually in the U.S., adding to the ~220,000 EGFR inhibitor patients.
- No financial figures, guidance, or material agreements were disclosed in the filing.
Financial Impact
No financial impact stated; pre-clinical and early clinical pipeline update with no revenue or cost figures.
Risk Factors
- Ex vivo results may not translate to human clinical outcomes; first-in-human study could fail or be delayed.
- ATR-04 trial expansion adds complexity; enrollment in new cohorts may be slow or produce different safety/efficacy profiles.
- Company has a $4M market cap and may need to raise additional capital to fund ongoing trials.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001493152-26-050882 |
| Exhibit: ex99-1.htm | 0001493152-26-050882 |
| Document: 0001493152-26-050882-index-headers.html | 0001493152-26-050882 |
| Document: 0001493152-26-050882-index.html | 0001493152-26-050882 |
| Document: 0001493152-26-050882.txt | 0001493152-26-050882 |
Track record
16 reports on AZTR
2 of 3 bullish or bearish reports moved the stock their way by T+60. Best: +38.73% at T+60 after the May 21, 2026 report. 3 of 3 went positive at some point.
Filters
- Nov 16, 2026today SC 13D Neutral 5/10 Entry $0.5805 Now $0.6090 +4.91% settles Feb 16
- Nov 12, 20264d ago Press Release Neutral 4/10 Entry $0.6084 Now $0.6090 +0.10% settles Feb 11
- Nov 12, 20264d ago 8-K Neutral 4/10 No price data
- Nov 12, 20265d ago SC 13G/A Neutral 2/10 Entry $0.6685 Now $0.6090 −8.90% settles Feb 10
- Nov 10, 20267d ago 8-K Neutral 3/10 Viewing Entry $0.6000 Now $0.6090 +1.50% settles Feb 8
- Nov 10, 20267d ago Press Release Neutral 3/10 Entry $0.6000 Now $0.6090 +1.50% settles Feb 8
- Oct 29, 202619d ago 8-K Neutral 3/10 Entry $0.7571 Now $0.6090 −19.56% settles Jan 27
- Oct 26, 202622d ago 8-K Neutral 4/10 Entry $1.53 Now $0.6090 −60.20% settles Jan 22
- Oct 22, 202626d ago 8-K Neutral 3/10 Entry $0.0715 Now $0.6090 +751.75% settles Jan 21
- Oct 1, 20266w ago 8-K Neutral 4/10 Entry $0.1285 Now $0.6090 +373.93% settles Dec 28
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers